Background Routine punch biopsies are considered to be standard care for diagnosing and subtyping basal cell carcinoma (BCC) when clinically suspected. Objectives We assessed the efficacy of a one-stop-shop concept using in vivo reflectance confocal microscopy (RCM) imaging as a diagnostic tool vs. standard care for surgical treatment in patients with clinically suspected BCC.
Basal cell carcinoma (BCC) is the most common type of skin cancer in white populations worldwide. Numerous studies have reported on the rising incidence of BCC causing a major burden on current healthcare systems. [1] [2] [3] [4] Punch biopsies are considered to be standard care not only to diagnose BCC when clinically suspected, but also to establish the histological subtype (superficial, nodular or aggressive) and subsequent excision margin. 5 However, studies identified in our previous systematic review have reported that a punch biopsy does not accurately diagnose the most aggressive BCC subtype in a substantial number of cases; sensitivity ranged from 61% to 85% and specificity ranged from 79% to 88%. 6 Moreover, noninvasive imaging devices have been developed that might revolutionize the diagnosis of the increasing number of cases of skin cancer. 7 Of those noninvasive imaging modalities, real-time in vivo reflectance confocal microscopy (RCM) has shown to be a promising technique for diagnosing and subtyping BCC. 8 In 2012, van der Geer et al. presented a new disease-management strategy for patients with BCC consisting of a onestop-shop concept with preoperative frozen section histology to confirm BCC diagnosis and divide into subtypes. 9 The onestop-shop concept implies that on the day of the initial outpatient clinic consultation, diagnosis and treatment would both take place.
We assessed the efficacy of a one-stop-shop concept using RCM as a diagnostic tool vs. standard care for surgical treatment in patients with clinically suspected BCC.
Patients and methods

Study design and participants
We performed this open-label, parallel-group, noninferiority, randomized controlled multicentre trial at the Department of Dermatology, Academic Medical Center, University of Amsterdam (coordinating tertiary referral centre) and the Department of Dermatology, the Netherlands Cancer Institute (participating tertiary referral centre), Amsterdam, the Netherlands. The study protocol has been previously published. 10 Consecutive eligible patients of 18 years and older with a clinically suspected, primary, untreated BCC, regardless of subtype and present for at least 1 month were prospectively enrolled. We excluded patients with lesions that were not suitable for conventional surgical excision, lesions in a high-risk location of the face (H-zone and ears), lesions larger than 20 mm, recurrent BCC, macroscopic ulcerating lesions and those with basal cell naevus syndrome. The study was conducted according to the principles of the Declaration of Helsinki (Fortaleza, Brazil, October 2013) and in accordance with the Medical Research Involving Human Subjects Act (WMO). The research protocol has been approved by ethics committees at both centres (NL50112.018.14). All participants gave written informed consent. The trial was registered with the Netherlands Trial Register (NTR5305) and with ClinicalTrials.gov (NCT02285790).
Randomization and masking
Patients were randomly allocated to the 'one-stop-shop' or 'standard care' treatment. Block randomization (1 : 1) was performed with random block sizes of two, four, six and eight. The allocation sequence was generated using an online computer-based program developed by the Clinical Research Unit of the Academic Medical Center to ensure concealment of allocation. Participants and investigators were not masked for treatment. Masking of the pathologist who assessed the histology of punch biopsies and/or surgical excision specimens was only partly possible because a punch-biopsy scar could be recognized during the assessment of the excision specimen.
Procedures
The initial clinical assessment, which usually included dermoscopy, was performed by experienced board-certified dermatologists. The one-stop-shop group received RCM (VivaScope 1500 â ; CaliberID, Henrietta, NY, U.S.A.; MAVIG GmbH, Munich, Germany) to diagnose and subtype BCC, followed by direct surgical excision. RCM was performed according to the previously published protocol for diagnosing clinically suspected BCC and for dividing BCC into subtypes. The standard-care group received planned excision after a punch biopsy was performed. The routine 3-mm punch biopsy was performed from the most elevated part of the lesion using infiltration anaesthesia (2% xylocaine/epinephrine 1 : 80 000). Biopsy specimens were subsequently analysed by a pathologist within 2 weeks. Surgical excision of the lesion with adequate margins was performed within the following 4 weeks after receiving the report of the punch biopsy. Excision specimens were analysed by the same pathologist.
BCCs were divided into superficial, nodular or aggressive subtypes (micronodular, infiltrating or basosquamous). The most aggressive histological BCC subtype (as determined by either RCM in the one-stop-shop group or as shown by punch biopsy in the standard-care group) determined the surgical excision margin [superficial and/or nodular (3 mm) vs. aggressive (5 mm) ]. An independent dermatologist or independent dermatology resident (supervised by a dermatologist) performed surgery under local anaesthetic (2% xylocaine/epinephrine 1:80 000) followed by primary wound closure in both treatment groups.
Assessment of the surgical excision specimen was performed by an experienced pathologist. Clinically suspected BCCs that were not confirmed by either RCM or a punch biopsy were surgically treated with a 3-mm excision margin.
Outcomes
The primary outcome was the proportion of patients with tumour-free margins on the final pathology report of the routinely processed tissue specimen after surgical treatment of BCC. Secondary outcomes were the proportion of accurately diagnosed BCCs by RCM and a punch biopsy including the most aggressive histological subtype, patients' throughput time, patient satisfaction and adverse events. The throughput time was defined by the total amount of time spent at our outpatient clinic for diagnosis and subsequent surgical treatment of the clinically suspected BCC, calculated from arrival at consultation until the end of surgical treatment.
Patients with histologically proven BCC in the surgical excision specimen were followed up at 3 months. A clinical evaluation of the postoperative scar was performed by a dermatologist or dermatology resident. Patient satisfaction was assessed using an adjusted version of a standardized questionnaire published by van Cranenburgh et al. 11 This questionnaire consists of six questions and uses a 5-point Likert scale (very satisfied, satisfied, not satisfied/not unsatisfied, unsatisfied, very unsatisfied) to assess the following domains:
effectiveness, safety, convenience, information, doctor-patient communication, and organization.
Statistical analysis
To test whether the RCM one-stop-shop concept was noninferior to standard care for surgical treatment of BCC, a prespecified noninferiority margin of 15% was used. A sample size of 38 patients with histologically proven BCC (excision specimen) per treatment group was needed to establish noninferiority with a power of 80%, considering an expected tumour-free margin BCC excision rate of 95% in the standardcare arm and a one-sided type I error of 5%. We recorded the characteristics of participants at baseline. These were summarized with descriptive statistics for each treatment group and tested using the t-test, the v 2 -test or Fisher's exact test.
We excluded from the analyses cases in which subsequent surgical excision of the clinically suspected BCC was not Three patients in the standard-care group did not receive subsequent surgical excision after the punch biopsy. For one patient the protocol was violated after the histological assessment of punch biopsy specimen showed actinic keratosis with no visible signs of the biopsied lesion on the day of surgery. Another patient with a histologically confirmed superficial BCC was mistakenly treated with PDT instead of surgery. The last patient with a histologically confirmed BCC developed a large leiomyosarcoma at the same localization. Surgical excision of the BCC was cancelled and the patient was referred to an oncological surgeon to treat the leiomyosarcoma.
performed. Reasons for not performing surgical excision were recorded. For the primary outcome we constructed a score based on a 90% confidence interval for the difference in proportions of patients with tumour-free margins after BCC excision between the one-stop-shop group and the standard-care group using the PropCIs package in R for the Miettinen and Nurminen method. 12, 13 The secondary outcomes groups were compared using the Wilcoxon rank sum test, the v 2 -test or Fisher's exact test. The statistical analysis was performed using Stata version 13 software (StataCorp, College Station, TX, U.S.A.).
Results Figure 1 shows the trial profile. Between 3 February 2015 and 2 October 2015 100 patients with clinically suspected BCC were randomly assigned to either the RCM one-stop-shop treatment group (n = 50) or standard-care treatment group (n = 50). The study period, including all follow-ups, ended on 30 August 2016. Baseline characteristics, except skin type, were not significantly different between the two groups (Table 1) . Overall, 95 patients underwent the assigned surgical treatment followed by primary wound closure and were included in the analyses (n = 48 in the one-stop-shop group and n = 47 in the standard-care group). A total of 73 (73 of 95, 77%) BCCs were histologically confirmed on surgical excision specimen, 40 BCCs in the one-stop-shop group and 33 in the standard-care group (Fig. 1) . Most of the BCCs had a superficial or nodular subtype (Table 2) . Among the 22 other lesions there was one melanoma, two squamous cell carcinomas, five cases of Bowen disease and 11 nonmalignant lesions. In the remaining three lesions, no residual signs of BCC were found after a punch biopsy had been performed. In the one-stop-shop group all 40 patients (100%) with BCC had tumour-free margins after surgical treatment. In the standard-care group 31 of 33 patients (94%) with BCC had tumour-free margins after surgical treatment. Of the two BCCs with an incomplete surgical excision margin, one had a superficial subtype and the other had a mixed subtype (superficial/nodular). For both patients with incomplete excisions, clinical follow-up was decided.
The difference in the proportion of patients with tumourfree margins after BCC excision between the one-stop-shop group and the standard-care group was À0Á06 (90% confidence interval À0Á17À0Á01). As the noninferiority limit was 0Á15, these data demonstrate that the RCM one-stop-shop care is noninferior to standard care. The confidence limit contains zero, which means that it is not possible to interpret these data as providing support for the superiority of the RCM onestop-shop care.
The time taken to perform RCM was recorded in 42 of the 48 clinically suspected lesions in the one-stop-shop group with a mean time of 13 min. In 38 of the 43 (88%) BCCs diagnosed by RCM, surgical excision specimens confirmed the diagnosis (Fig. 1) . The other five of 48 clinically suspected lesions tested negative for BCC presence by RCM. Of those, two BCCs were later histologically confirmed by excision specimen, one ulcerating lesion and one lesion with a superficial crust. In 29 of 38 (76%) correctly diagnosed BCCs, RCM identified the most aggressive histological subtype.
In the standard-care group (n = 48) patients received the diagnosis from the punch biopsy within 2 weeks after the initial appointment. The time needed for the pathologist to Patients who were taking immunosuppressive drugs such as oral steroids, methotrexate, ciclosporin for suppression of immunological disorder, or to prevent transplant rejection. establish the histological diagnosis and subtype of the punch biopsy was not recorded. In 31 of 34 (91%) BCCs diagnosed by a punch biopsy, surgical excision specimen confirmed the diagnosis (Fig. 1) . The other 13 of 47 clinically suspected lesions tested negative for BCC presence by punch biopsy. Of those, two BCCs were later histologically confirmed by excision specimen. In 28 of 31 (90%) correctly diagnosed BCCs, a punch biopsy identified the most aggressive histological subtype. The mean throughput time for patients in the one-stopshop group receiving direct surgical treatment (n = 48) was 2 h 23 min. In the standard-care group (n = 47) the mean time that patients spent at our outpatient clinic during the initial visit for the punch biopsy was 1 h 15 min. The throughput time could not be calculated because the time spent at the hospital during the following visit for surgical treatment was not recorded.
All patients with a histologically proven BCC on surgical excision specimen (n = 73) were seen at a postoperative follow-up 3 months later. The mean follow-up time was 18 weeks in the one-stop-shop group (n = 40) and 21 weeks in the standard-care group (n = 33). The average time between the initial visit and surgical treatment in the standard-care group (n = 33) was almost 10 weeks (66 days).
Patients in the one-stop-shop group rated treatment convenience significantly higher (5-point Likert scale mean 4Á63) compared with patients in the standard-care group (5-point Likert scale mean 4Á32, P = 0Á031) ( Table 3) .
Adverse reactions that were reported in this trial included four patients in the one-stop-shop group (n = 48) with postoperative wound infections. In all cases the infection was successfully treated with oral antibiotics, without the need for hospitalization. One patient in the standard-care group (n = 50) who had been using anticoagulant medication developed excessive postoperative bleeding, which required hospitalization for 3 days. She fully recovered. This was reported as the only serious adverse event.
Discussion
Our findings show that a one-stop-shop concept using RCM was noninferior to standard care in terms of tumour-free margins after surgical treatment of BCC. These results suggest that an RCM one-stop-shop concept could be considered in clinical dermatology practice as a new treatment strategy for primary BCC, evidently depending on factors such as availability of RCM, size and site of the lesion, patient preference and whether direct surgical excision is feasible. This is the first randomized controlled trial that investigates the efficacy of a one-stop-shop concept using RCM skin imaging to diagnose and subtype primary BCC prior to surgical treatment. Current literature indicates that incomplete excision-rate numbers after conventional surgical treatment of BCC may vary according to tumour localization, histological subtype and training of the treating physician.
14, 15 We intentionally aimed to investigate primary BCCs smaller than 20 mm at low-risk localization and predefined a 95% tumourfree margin rate as acceptable. The exclusion of large BCCs and/or high-risk localizations might have positively influenced the proportion of successfully treated patients in both treatment groups. This study seems relevant to the rising number of BCCs seen in clinical dermatology practice. Although BCC has a good prognosis, delay in diagnosis and appropriate treatment may result in extra public health costs. 16 Noninvasive imaging techniques such as RCM can aid in earlier detection of BCC as opposed to painful routine skin biopsies, 17 even in BCCs that are invisible to the naked eye. 18 In addition to early diagnosis, another important advantage of the RCM one-stop-shop is direct treatment for patients with BCC. This was supported by our results regarding patient satisfaction. Patients in the onestop-shop group rated treatment convenience (mean 4Á63) significantly higher compared with patients in the standard-care group (mean 4Á32, P = 0Á031). High patient satisfaction was also reported in the one-stop-shop performed by van der Geer et al. in 2012. 9 However, in their pilot study fresh frozen sections of 4-mm punch biopsies were used to diagnose 16 BCCs and divide these BCCs into subtypes. This resulted in a higher throughput time of 4 h 7 min compared with our mean throughput time of 2 h 23 min in the RCM one-stop-shop. The strengths of this study include the prospective investigator-initiated pragmatic design, the combination of diagnosis and treatment as a single entity and the randomization of these care strategies. By linking diagnostic testing to management actions, we assessed how the introduction of RCM impacts the current diagnostic pathway for clinically suspected BCC. Such a test-treatment pathway helps to map out the ideal context in which RCM may be used as opposed to standard care. 19 The study limitations include the number of excluded participants, most of which were excluded owing to BCC in high-risk areas of the face. The VivaScope 1500 â device that was used in our study is not suitable for imaging these specific localizations. However, by incorporating the more recently introduced VivaScope 3000 â flexible handheld version (VivaScope 3000 â ; CaliberID; MAVIG GmbH), accessibility to the more concave and convex high-risk head and neck areas would be possible. 20 The misinterpretation of confocal images in our study may have been related to a relatively limited experience of using RCM. Both investigators (D.J.K. and Y.S.E.) had less than 1 year of experience prior to the start of the study. A higher level of RCM experience seems to result in higher diagnostic accuracy. 21, 22 This was confirmed in a recent retrospective article that compared the interobserver agreement of specific confocal skin cancer feature recognition between nine dermatologists with varying RCM experience. 23 Unfortunately, we were not able to calculate the throughput time in the standard-care group as the time taken for surgical treatment on the second visit was not recorded.
Another study limitation was the short postoperative follow-up time of 3 months. A longer clinical follow-up of at least 1 year would be needed to detect signs of BCC recurrence. Lastly, patient satisfaction was not assessed in the 22 patients without a histologically confirmed BCC in the surgical excision specimen.
In terms of external validity, performing a punch biopsy for clinically suspected BCC is recommended by international guidelines, although it may not be standard care for all practising dermatologists. 24, 25 In addition, surgical treatment of superficial BCC may not be in line with daily practice. 26 However, in our test-treatment pathway it was important to confirm all types of BCC histologically in the surgical excision specimen. Furthermore, the pathologists who assessed the surgical excision specimen were not blinded to the results of the punch biopsy specimen. This is an important potential source of bias in favour of punch biopsy as a diagnostic tool.
In conclusion, this trial showed that a one-stop-shop concept with RCM was noninferior to standard care in terms of tumour-free margins after surgical treatment of BCC. The proposed new treatment strategy seems suitable in facilitating early diagnosis and direct treatment for the rising number of patients with BCC.
